- Home
- MGLD vs LTRN Comparison
MGLD vs LTRN Comparison
Compare MGLD & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- LTRN
- Stock Information
- Founded
- MGLD 1996
- LTRN 2013
- Country
- MGLD United States
- LTRN United States
- Employees
- MGLD N/A
- LTRN N/A
- Industry
- MGLD Finance/Investors Services
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- LTRN Health Care
- Exchange
- MGLD Nasdaq
- LTRN Nasdaq
- Market Cap
- MGLD 44.8M
- LTRN 36.0M
- IPO Year
- MGLD N/A
- LTRN 2020
- Fundamental
- Price
- MGLD $1.04
- LTRN $3.83
- Analyst Decision
- MGLD
- LTRN Strong Buy
- Analyst Count
- MGLD 0
- LTRN 1
- Target Price
- MGLD N/A
- LTRN $25.00
- AVG Volume (30 Days)
- MGLD 15.1K
- LTRN 75.1K
- Earning Date
- MGLD 11-07-2025
- LTRN 11-06-2025
- Dividend Yield
- MGLD N/A
- LTRN N/A
- EPS Growth
- MGLD N/A
- LTRN N/A
- EPS
- MGLD N/A
- LTRN N/A
- Revenue
- MGLD $31,205,000.00
- LTRN N/A
- Revenue This Year
- MGLD N/A
- LTRN N/A
- Revenue Next Year
- MGLD N/A
- LTRN N/A
- P/E Ratio
- MGLD N/A
- LTRN N/A
- Revenue Growth
- MGLD N/A
- LTRN N/A
- 52 Week Low
- MGLD $0.64
- LTRN $2.55
- 52 Week High
- MGLD $2.10
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- MGLD 57.88
- LTRN 39.82
- Support Level
- MGLD $1.01
- LTRN $3.74
- Resistance Level
- MGLD $1.15
- LTRN $4.26
- Average True Range (ATR)
- MGLD 0.08
- LTRN 0.34
- MACD
- MGLD 0.01
- LTRN -0.06
- Stochastic Oscillator
- MGLD 65.62
- LTRN 9.35
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.